Every 8-K that WW International, Inc. (WW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow WW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WW filings page.
WW International, Inc. (WW) announced that it has appointed Stephen J. Bye as President and Chief Executive Officer and as a director, effective on a mutually agreed date on or prior to November 27, 2026. The board will expand from six to seven directors when he joins, and he will serve until the 2027 annual meeting or earlier departure.
WW entered into an employment agreement providing a $850,000 base salary, a target annual cash bonus of 125% of salary (with 2026 bonus guaranteed at target, pro-rated from his start date), a $1.5 million signing bonus paid in 2027 and 2028, and equity incentives including a $1.0 million signing RSU award and a $5.1 million initial equity grant, plus future annual equity grants from 2028 at least equal to 300% of salary. The agreement includes severance and accelerated vesting protections upon certain terminations, including enhanced benefits after a Change in Control. The interim Office of the Chief Executive will dissolve when Bye assumes the CEO role, with existing executives continuing as CFO and COO.
WW International reported Q2 2026 revenue of $162.3 million, compared with $189 million in combined Q2 2025, as Behavioral subscription revenue declined while the higher-priced Clinical offering expanded. Gross margin was 70.3%, Adjusted gross margin 73.6%, and net income was $14.1 million, with Adjusted EBITDA of $39.8 million (24.5% margin).
Total End of Period subscribers were 2.489 million, down 21.4% year-over-year, driven by a 24.6% decline in Behavioral subscribers, while End of Period Clinical subscribers grew 55.7% to 197 thousand. Core+, the higher-value Behavioral tier, reached 541 thousand subscribers and delivered a third consecutive quarter of sequential growth. Q2 marketing expense was $47.9 million, or 29.5% of revenue, after elevated peak-season spending in Q1. The company used $36.8 million of cash to reduce term-loan principal by $41.4 million, cutting annualized interest expense by about $4 million and ending the quarter with $101.5 million in cash. WW reaffirmed full-year 2026 guidance for $620–$635 million of revenue and $105–$115 million of Adjusted EBITDA.
WW International, Inc. reported the results of its 2026 annual meeting of shareholders held on June 12, 2026. Shareholders elected six directors to one-year terms ending at the 2027 annual meeting. Each director nominee received substantially more votes "for" than "against," with additional broker non-votes recorded.
Shareholders also ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers. All three proposals passed with comfortable voting margins.
WW International detailed the severance arrangements for former President and Chief Executive Officer Tara Comonte following her previously disclosed resignation effective March 31, 2026. On May 14, 2026, the company and Ms. Comonte entered into a Settlement Agreement and General Release and Waiver of Claims.
Under this agreement, Ms. Comonte will receive a cash settlement totaling $1,850,000, paid in two installments: $545,205.48 after the release becomes irrevocable and $1,304,794.52 on October 1, 2026. WW will also pay a gross amount of $150,000 directly to her legal counsel for attorneys’ fees and costs.
The agreement includes mutual releases of claims between the parties, a cooperation covenant benefiting the company, mutual non-disparagement, and mutual confidentiality regarding the negotiations and circumstances leading to the settlement. WW notes that the full Settlement Agreement will be filed as an exhibit to its Form 10-Q for the quarter ended June 30, 2026.
WW International reported first quarter 2026 results with revenue of $168.3 million and a net loss of $52.0 million. Subscription revenue was $167.4 million, including $128.5 million from Behavioral offerings and $38.8 million from faster‑growing Clinical offerings, where Clinical subscription revenue rose 31.8% year‑over‑year.
Total end‑of‑period subscribers were 2.659 million, with 2.463 million Behavioral and 197 thousand Clinical subscribers, as mix shifts toward higher‑value tiers lifted ARPU to $20.59, up 13% year‑over‑year. Adjusted EBITDA was a loss of $1.8 million, as marketing spending was front‑loaded to promote Med+ and GLP‑1 offerings, while Adjusted Gross Margin remained high at 73.6%.
The company ended the quarter with $120.9 million of cash and cash equivalents and long‑term debt of $438.6 million. It plans in Q2 to use $37 million of cash to retire $42 million of term‑loan principal, which is expected to cut annualized interest expense by approximately $4 million. Management reaffirmed full‑year 2026 guidance for revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million, and continues to expect cash generation over the remaining quarters of 2026.
WW International plans to use up to $40 million of cash to prepay and reduce the principal on its outstanding term loan, lowering its debt balance. This action is described as part of broader efforts to strengthen liquidity and deleverage the balance sheet.
The company also reaffirmed its first quarter 2026 end-of-period subscriber estimates and full-year 2026 financial guidance previously issued on March 16, 2026. Based on that guidance, management expects to generate cash over the rest of the year after heavier first-quarter marketing spending.
WW International, Inc. appointed Heather Thiltgen to its Board of Directors, effective April 20, 2026, increasing the Board size to six members. She will serve until the Company’s 2026 annual meeting of shareholders and is expected to stand for election at that meeting.
The Board determined that Ms. Thiltgen is an independent director under Nasdaq rules and also named her to the Compensation and Benefits Committee. She will receive an annual cash retainer of $90,000 plus $12,500 for committee service, prorated for fiscal 2026, and may receive restricted stock units with a target value of $135,000 following shareholder election.
WW International, Inc. reported a board change and interim executive pay adjustments. Director Michael Mason resigned from the board effective immediately for personal reasons, and the company stated his departure did not involve any disagreement over operations, policies, or practices.
Following his resignation, the board reduced its size from six to five directors. The company previously created an Interim Office of the Chief Executive (IOCE), led by CFO Felicia DellaFortuna and COO Jonathan Volkmann. In recognition of their expanded interim leadership duties, each will receive a $150,000 cash payment in April 2026 and, if they continue in the IOCE from July 1, 2026, a monthly cash fee of $50,000. Their annual cash bonus targets were also increased from 50% to 75% of base salary for the 2026 plan year.
WW International, Inc. filed an amended report to detail new board committee assignments and its interim leadership approach. Following their recent election to the Board, Lisa Gavales was appointed to the Compensation and Benefits Committee and the Strategy and Finance Committee, while Sue E. Gove joined the Audit Committee and the Nominating and Corporate Governance Committee, effective April 8, 2026.
The Board also confirmed it will continue operating under the existing Office of the CEO structure, led by CFO Felicia DellaFortuna and COO Jon Volkmann, and will not appoint an interim CEO. The Board states this arrangement provides experienced leadership and continuity while a permanent CEO search proceeds with the help of an executive search firm.
WW International, Inc., known as Weight Watchers, appointed Lisa Gavales and Sue E. Gove as independent directors effective April 7, 2026. They will serve until the 2026 annual meeting and are expected to stand for election.
The Board increased to six directors, all classified as independent under Nasdaq listing standards. Each new director will receive an annual cash retainer of $90,000, plus $12,500 per year for each standing Board committee membership, with 2026 amounts prorated. Subject to their election at the 2026 annual meeting, they will be eligible for an annual restricted stock unit grant targeting $135,000 in value.
The company highlights their deep consumer, digital, turnaround and financial leadership experience to support Weight Watchers’ strategic transformation and growth focus in science-backed weight management and digital health.
WW International (Weight Watchers) announced major leadership and board changes. CEO Tara Comonte resigned effective March 31, 2026, and the company created an Interim Office of the CEO led by CFO Felicia DellaFortuna and COO Jonathan Volkmann while the board conducts a search for a new CEO.
Chief Legal and Administrative Officer and Secretary Jacqueline Cooke will depart April 10, 2026, and will receive a cash separation payment, extended health benefits and legal fee reimbursement under a Separation Agreement. Senior vice president Debra Cotter will become chief legal officer and secretary.
Directors Julie Bornstein and Fallon O’Connor also resigned, and the board reduced its size from seven to four members and amended its bylaws to allow as few as three directors. The company reaffirmed its first quarter 2026 subscriber estimates and full-year 2026 financial guidance.
WW International reported mixed fourth quarter and full-year 2025 results as it transitions from a traditional behavioral weight-loss model to an integrated clinical and GLP-1 focused platform. Q4 2025 total revenue was $163 million, down 12% year-over-year, with behavioral subscription revenue falling 17% while clinical subscription revenue grew 32% to $27 million. The company posted a Q4 net loss of $6 million, a net loss margin of 3.6%, and Adjusted EBITDA of $18 million with an 11.1% margin, down from $46 million and a 25.1% margin a year earlier.
Management highlighted strong momentum in its clinical Med+ offering and GLP-1 Success Program, noting end-of-period clinical subscribers rose 42% to 130,000 within a total subscriber base of 2.8 million. For 2026, WW guided to revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million, and estimated first quarter 2026 end-of-period subscribers of about 2.65 million, including roughly 200,000 clinical subscribers. Following its June 2025 Chapter 11 reorganization, WW ended 2025 with $160 million of cash and a significantly reduced term loan of $465 million, cutting total debt by more than 70% from $1.6 billion and improving net debt to about $305 million.
WW International furnished an 8-K announcing financial results for the fiscal quarter ended September 30, 2025. The company issued a press release and a Shareholder Letter, provided as Exhibits 99.1 and 99.2.
The information in Item 2.02 is being furnished and is not deemed “filed” under the Exchange Act, and will be incorporated by reference only if specifically stated in a future filing.
WW International furnished a press release and a shareholder letter announcing financial results for its fiscal quarter ended June 30, 2025. The filing lists those materials as Exhibits 99.1 and 99.2 and the cover page in Inline XBRL as Exhibit 104. The company states the materials are being furnished, not "filed," and says they will not be incorporated by reference into registration statements except by specific reference.
WW International, Inc. (Nasdaq: WW) filed an 8-K on 7 July 2025 announcing a governance change. The Board unanimously elected Fallon O’Connor-Brooks as an independent director effective 8 July 2025, with a term running until the 2026 annual meeting. Concurrently, the Board created a new Strategy and Finance Committee (effective 1 July 2025) and named Ms. O’Connor its first member.
Compensation mirrors the company’s standard package for non-employee directors:
- $90,000 annual cash retainer, paid quarterly
- Additional $10,000 annual cash fee for SF Committee service
- Proration applies for the remainder of fiscal 2025
- The Board expects to introduce a new equity grant program for non-employee directors later in fiscal 2025
No arrangements or related-party transactions were disclosed, and Nasdaq independence requirements are met. The filing also furnishes a press release (Exhibit 99.1) regarding the appointment. No financial results, transactions, or operational updates were included.
WW International (OTC:WGHTQ) announced its successful emergence from Chapter 11 bankruptcy on June 24, 2025, following court approval of its prepackaged reorganization plan. The company has secured a new $465 million senior secured credit facility maturing in 2030.
Key restructuring outcomes include: (1) Discharge of approximately $1.116 billion in pre-petition credit facilities and $500 million in senior secured notes, (2) Cancellation of all previous equity securities, and (3) Implementation of new financing terms including interest rates of base rate plus 5.80% or Term SOFR plus 6.80%.